XML 97 R62.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Acquisitions - Narrative (Details)
12 Months Ended
Feb. 08, 2018
USD ($)
milestone_payment
Nov. 16, 2016
USD ($)
milestone_payment
shares
Jan. 12, 2016
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Business Acquisition [Line Items]            
Change in fair value of contingent consideration       $ 0 $ (763,000) $ (7,377,000)
Non-Alcohol Docetaxel Injection            
Business Acquisition [Line Items]            
Change in fair value of contingent consideration           6,200,000
Eagle Biologics            
Business Acquisition [Line Items]            
Payment for business acquisition   $ 27,209,000        
Change in fair value of contingent consideration       $ 0 $ (1,201,000) $ 1,200,000
Business combination, consideration transferred   $ 45,255,000        
Shares issued to acquire business (in shares) | shares   40,200        
Business combination, stock consideration transferred, amount   $ 3,046,000        
Number of milestone payments | milestone_payment   4        
Docetaxel product rights | Non-Alcohol Docetaxel Injection            
Business Acquisition [Line Items]            
Payment for business acquisition     $ 4,850,000      
Business combination, consideration transferred     $ 11,220,000      
Royalties on Gross Profits | Docetaxel product rights | Non-Alcohol Docetaxel Injection            
Business Acquisition [Line Items]            
Royalties, percentage of gross profits     25.00%      
Milestone Payments | Eagle Biologics            
Business Acquisition [Line Items]            
Contingent consideration liability $ 48,000,000 $ 48,000,000        
Business combination, consideration transferred, including contingent consideration   $ 78,000,000        
Number of milestone payments | milestone_payment 4          
Payment of lump sum milestone arrangement $ 15,000,000